Immuno-oncology (I/O) is considered one of the most promising therapeutic avenues for treating cancer. Modern I/O relies on several strategies to stimulate the immune system and overcome the natural defenses inherent to cancer. However, even the most advanced I/O therapies are only effective in a minority of patients due to lack of response and dose-limiting toxicities that limit full clinical potential. There is a great need for new treatments and technologies with an acceptable safety profile that offer compatibility with other therapeutic modalities. Some of these challenges will find solutions with our INTASYL™ self-delivering technology.
Phio is maximizing the value of the self-delivering RNAi technology for I/O by
- Developing adoptive cell therapy (ACT) products with increased antitumor effectiveness in partnering with leading providers
- Developing RNAi drugs directly targeting immunosuppression in the tumor microenvironment (TME)